Depression and epilepsy: Epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence

Epilepsy and Behavior

Volumn 24, Issue 2, 2012, Pages 156-168

  Kanner, Andres M ^a   Schachter, Steven C ^a   Barry, John J ^a   Hersdorffer, Dale C ^a   Mula, Marco ^a   Trimble, Michael ^a   Hermann, Bruce ^a   Ettinger, Alan E ^a   Dunn, David ^a   Caplan, Rochelle ^a   Ryvlin, Philippe ^a   Gilliam, Frank ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Major depressive episodes; Peri ictal depressive episodes; Selective serotonin reuptake inhibitors; Serotonin receptors; Suicidality

Indexed keywords

COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; EPILEPSY; HUMAN; MOOD DISORDER; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; PATHOGENESIS; REVIEW; SEIZURE;

ANIMALS; BRAIN CHEMISTRY; CEREBRAL CORTEX; COMORBIDITY; DEPRESSION; DISEASE MODELS, ANIMAL; EPILEPSY; EPILEPSY, TEMPORAL LOBE; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RATS; RESEARCH DESIGN;

EID: 84861409043     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2012.01.007     Document Type: Review

References (184)

1. Temkin O. The falling sickness 1950, Johns Hopkins University Press, Baltimore.
2. Trimble M.R., Reynolds E.H. Anticonvulsant drugs and mental symptoms: a review. Psychol Med 1976, 6(2):169-178.
3. Trimble M. Anticonvulsant drugs, behavior, and cognitive abilities. Curr Dev Psychopharmacol 1981, 6:65-91.
4. Robertson M.M., Trimble M.R., Townsend H.R. Phenomenology of depression in epilepsy. Epilepsia 1987, 28(4):364-372.
5. Robertson M.M., Trimble M.R. The treatment of depression in patients with epilepsy. A double-blind trial. J Affect Disord 1985, 9(2):127-136.
6. Robertson M.M. Suicide and epilepsy. Epilepsy, a comprehensive text book 1996, 2141-2152. Raven Press, New York. J. Engel (Ed.).
7. Robertson M.M., Trimble M.R. Depressive illness in patients with epilepsy: a review. Epilepsia 1983, 24(Supplement 2):S109-S116.
8. Gilliam F., Hecimovic H., Sheline Y. Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav 2003, 4(Suppl. 4):S26-S30.
9. Hitiris N., Mohanraj R., Norrie J., Sills G.J., Brodie M.J. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007, 75(2-3):192-196.
10. Ring H.A., Crellin R., Kirker S., Reynolds E.H. Vigabatrin and depression. J Neurol Neurosurg Psychiatry 1993, 56(8):925-928.
11. FDA, US Department of Health and Human Services Statistical review and evaluation: antiepileptic drugs and suicidality May 23 2008, Washington.
12. Hesdorffer D.C., Hauser W.A., Olafsson E., Ludvigsson P., Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol 2005, 59:35-41.
13. Blumer D. Dysphoric disorders and paroxysmal affects: recognition and treatment of epilepsy-related psychiatric disorders. Harv Rev Psychiatry 2000, 8:8-17.
14. Mula M. The interictal dysphoric disorder. The neuropsychiatry of epilepsy 2011, 80-87. Cambridge University Press, Cambridge. 2nd edition. M.R. Trimble, B. Schmitz (Eds.).
15. Mendez M.F., Cummings J.L., Benson D.F. Depression in epilepsy: significance and phenomenology. Arch Neurol 1986, 43:766-770.
16. Kanner A.M. Depression and epilepsy: a new perspective on two closely related disorders. Epilepsy Curr 2006, 6:141-146.
17. Ettinger A., Reed M., Cramer J., et al. Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology 2004, 63:1008-1014.
18. Trimble M.R. The psychoses of epilepsy 1991, Raven Press, NY.
19. Schmitz E.B., Moriarty J., Costa D.C., et al. Psychiatric profiles and patterns of cerebral blood flow in focal epilepsy: interactions between depression, obsessionality, and perfusion related to the laterality of the epilepsy. J Neurol Neurosurg Psychiatry 1997, 62:458-463.
20. van Elst L.T., Woermann F.G., Lemieux L., Trimble M.R. Amygdala enlargement in dysthymia-a volumetric study of patients with temporal lobe epilepsy. Biol Psychiatry 1999, 46(12):1614-1623.
21. Schmitz B. The effects of antiepileptic drugs on behavior. The neuropsychiatry of epilepsy 2002, 241-255. Cambridge University Press, Cambridge. M.R. Trimble, B. Schmitz (Eds.).
22. Trimble M.R. Antiepileptic drugs and suicide. The neuropsychiatry of epilepsy 2011, 143-152. Cambridge University Press, Cambridge. 2nd edition. M.R. Trimble, B. Schmitz (Eds.).
23. Hesdorffer D.C., Hauser W.A., Annegers J.F., Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000, 47:246-249.
24. Hesdorffer D.C., Ludvigsson P., Hauser W.A., Olafsson E., Kjartansson O. Co-occurrence of major depression or suicide attempt with migraine with aura and risk for unprovoked seizure. Epilepsy Res 2007, 75:220-223.
25. Forsgren L., Nystrom L. An incident case-referent study of epileptic seizures in adults. Epilepsy Res 1990, 6:66-81.
26. Kanner A.M., Byrne R., Chicharro A., Wuu J., Frey M. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology 2009, 72:793-799.
27. Hitiris N., Mohanraj R., Norrie J., Sills G.J., Brodie M.J. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007, 75:192-196.
28. Tellez-Zenteno J.F., Patten S.B., Jette N., Williams J., Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007, 48:2336-2344.
29. Alper K., Schwartz K.A., Kolts R.L., Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007, 62:345-354.
30. Cramer J.A., Blum D., Fanning K., Reed M. The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav 2004, 5:337-342.
31. Ettinger A.B., Weisbrot D.M., Nolan E.E., et al. Symptoms of depression and anxiety in pediatric epilepsy patients. Epilepsia 1998, 39:595-599.
32. Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996, 35:705-715.
33. Andreasen N.C., Endicott J., Spitzer R.L., Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch Gen Psychiatry 1977, 34:1229-1235.
34. Bowman E.S., Markand O.N. Psychodynamics and psychiatric diagnoses of pseudoseizure subjects. Am J Psychiatry 1996, 153:57-63.
35. Benbadis S.R., Allen Hauser W. An estimate of the prevalence of psychogenic non-epileptic seizures. Seizure 2000, 9:280-281.
36. Sigurdardottir K.R., Olafsson E. Incidence of psychogenic seizures in adults: a population-based study in Iceland. Epilepsia 1998, 39:749-752.
37. Duncan R. Psychogenic nonepileptic seizures: diagnosis and initial management. Expert Rev Neurother 2010, 10:1803-1809.
38. Blumer D., Montouris G., Davies K. The interictal dysphoric disorder: recognition, pathogenesis, and treatment of the major psychiatric disorder of epilepsy. Epilepsy Behav 2004, 5:826-840.
39. Vaaler AE, Morken G, Iversen VC, Kondziella D, Linaker OM. Acute Unstable Depressive Syndrome (AUDS) is associated more frequently with epilepsy than major depression. BMC Neurol 10:67.
40. Jonas B.S., Wagener D.K., Lando J.F., Feldman J.J. Symptoms of anxiety and depression as risk factors for development of asthma. J Appl Biobehav Res 1999, 4:91-110.
41. Eaton W.W., Armenian H., Gallo J., Pratt L., Ford D.E. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 1996, 19:1097-1102.
42. Breslau N., Davis G.C., Schultz L.R., Peterson E.L. Joint 1994 Wolff Award Presentation. Migraine and major depression: a longitudinal study. Headache 1994, 34:387-393.
43. Cizza G., Ravn P., Chrousos G.P., Gold P.W. Depression: a major, unrecognized risk factor for osteoporosis?. Trends Endocrinol Metab 2001, 12:198-203.
44. Pratt L.A., Ford D.E., Crum R.M., Armenian H.K., Gallo J.J., Eaton W.W. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996, 94:3123-3129.
45. Schuurman A.G., van den Akker M., Ensinck K.T., et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002, 58:1501-1504.
46. Jonas B.S., Mussolino M.E. Symptoms of depression as a prospective risk factor for stroke. Psychosom Med 2000, 62:463-471.
47. Fann J.R., Burington B., Leonetti A., Jaffe K., Katon W.J., Thompson R.S. Psychiatric illness following traumatic brain injury in an adult health maintenance organization population. Arch Gen Psychiatry 2004, 61:53-61.
48. Geerlings M.I., Schoevers R.A., Beekman A.T., et al. Depression and risk of cognitive decline and Alzheimer's disease. Results of two prospective community-based studies in The Netherlands. Br J Psychiatry 2000, 176:568-575.
49. Walsh B.T., Seidman S.N., Sysko R., Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002, 287:1840-1847.
50. Whittington C.J., Kendall T., Fonagy P., Cottrell D., Cotgrove A., Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004, 363:1341-1345.
51. Breslau N., Davis G.C., Andreski P. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psychiatry Res 1991, 37:11-23.
52. Ludvigsson P., Hesdorffer D., Olafsson E., Kjartansson O., Hauser W.A. Migraine with aura is a risk factor for unprovoked seizures in children. Ann Neurol 2006, 59:210-213.
53. Velioglu S.K., Boz C., Ozmenoglu M. The impact of migraine on epilepsy: a prospective prognosis study. Cephalalgia 2005, 25:528-535.
54. Kanner A.M. Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin 2009, 27:865-880.
55. Pucilowski O., Overstreet D.H., Rezvani A.H., Janowsky D.S. Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiol Behav 1993, 54:1215-1220.
56. Pucilowski O., Overstreet D.H. Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains. Brain Res Bull 1993, 32:471-475.
57. Mazarati A.M., Siddarth P., Baldwin R.A., et al. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008, 131:2071-2083.
58. Jones N.C., Kumar G., O'Brien T.J., Morris M.J., Rees S.M., Salzberg M.R. Anxiolytic effects of rapid amygdala kindling, and the influence of early life experience in rats. Behav Brain Res 2009, 12(203(1)):81-87.
59. Salzberg M., Kumar G., Supit L., et al. Early postnatal stress confers enduring vulnerability to limbic epileptogenesis. Epilepsia 2007, 48(11):2079-2085.
60. Gilby K.L., Sydserff S., Patey A.M., et al. Postnatal epigenetic influences on seizure susceptibility in seizure-prone versus seizure-resistant rat strains. Behav Neurosci 2009, 123(2):337-346.
61. Zobel A., Wellmer J., Schulze-Rauschenbach S., et al. Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. Eur Arch Psychiatry Clin Neurosci 2004, 254(5):303-311.
62. Mazarati A.M., Shin D., Kwon Y.S., et al. Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol Dis 2009, 34(3):457-461.
63. Kumar G., Couper A., O'Brien T.J., et al. The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology 2007, 32(7):834-842.
64. López J.F., Chalmers D.T., Little K.Y., Watson S.J. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998, 15(43(8)):547-573.
65. Sapolsky R.M. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000, 15(48(8)):755-765.
66. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925-935. (b).
67. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 15(22(8)):3251-3261.
68. Bowley M.P., Drevets W.C., Ongur D., Price J.L. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002, 52:404-412.
69. Rajkowska G., Miguel-Hidalgo J.J., Wei J., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45(9):1085-1098.
70. Cotter D.R., Pariante C.M., Everall I.P. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001, 55:585-595.
71. Cotter D., Mackay D., Landau S., Kerwin R., Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001, 58:545-553.
72. Cotter D., Mackay D., Chana G., Beasley C., Landau S., Everall I.P. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002, 12:386-394.
73. Öngür D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998, 95:13290-13295.
74. Crossin K.L., Tai M.H., Krushel L.A., Mauro V.P., Edelman G.M. Glucocorticoid receptor pathways are involved in the inhibition of astrocyte proliferation. Proc Natl Acad Sci U S A 1997, 94:2687-2692.
75. Machado-Vieira R., Salvadore G., Ibrahim L.A., Diaz-Granados N., Zarate C.A. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des 2009, 15(14):1595-1611.
76. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005, 10(10):808-819.
77. Bonanno G., Giambelli R., Raiteri L., et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005, 25:3270-3279.
78. Robinson R., Drafts B., Fisher J. Fluoxetine increases GABAA receptor activity through a novel modulatory site. J Pharmacol Exp Ther 2003, 304:978-984.
79. Brambilla P., Perez J., Barale F., Schettini G., Soares J.C. GABAergic dysfunction in mood disorders. Mol Psychiatry 2003, 8:721-737.
80. Zink M., Vollmayr B., Gebicke-Haerter P.J., Henn F.A. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 2010, 58(2):465-473.
81. Zarate C.A., Quiroz J., Payne J., Manji H.K. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002, 36:35-83.
82. Zeng L.H., Bero A.W., Zhang B., Holtzman D.M., Wong M. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2010, 37(3):764-771.
83. Vezzani A., Balosso S., Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 2008, 22:797-803.
84. Kalliolias G.D., Liossis S.N. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008, 17:349-359.
85. Dunn A.J., Swiergiel A.H., de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev 2005, 29:891-909.
86. Mazarati A.M., Shin D., Sankar R., et al. Comorbidity between epilepsy and depression: role of hippocampal interleukin-1β. Neurobiol Dis 2010, 37:461-467.
87. Jobe P.C. Affective disorder and epilepsy comorbidity in the genetically epilepsy prone-rat (GEPR). Depression and brain dysfunction 2006, 121-157. Taylor & Francis, London. F. Gilliam, A.M. Kanner, Y.I. Sheline (Eds.).
88. Jobe P.C., Mishra P.K., Browning R.A., et al. Noradrenergic abnormalities in the genetically epilepsy-prone rat. Brain Res Bull 1994, 35:493-504.
89. Meldrum B.S., Anlezark G.M., Adam H.K., et al. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology (Berl) 1982, 76:212-217.
90. Yanagita T., Wakasa Y., Kiyohara H. Drug-dependence potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav 1980, 12:155-161.
91. Piette Y., Delaunois A.L., De Shaepdryver A.F., et al. Imipramine and electroshock threshold. Arch Int Pharmacodyn Ther 1963, 144:293-297.
92. Polc P., Schneeberger J., Haefely W. Effects of several centrally active drugs on the sleep wakefulness cycle of cats. Neuropharmacology 1979, 18:259-267.
93. Ye Z., Lu Y., Sun H., Cheng H., Xu T., Zhou J. Fluoxetine inhibition of glycine receptor activity in rat hippocampal neurons. Brain Res 2008, 1239:77-84.
94. 1A receptors. J Neurochem 2004, 89:834-843.
95. Jones N.C., Salzberg M.R., Kumar G., Couper A., Morris M.J., O'Brien T.J. Elevated anxiety and depressive-like behavior in a rat model of genetic generalized epilepsy suggesting common causation. Exp Neurol 2008, 209:254-260.
96. Kanner A.M. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry 2003, 54(3):388-398.
97. Barry J.J., Ettinger A.B., Friel P., et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 2008, 13(Suppl. 1):S1-S29.
98. Bromfield E.B., Altshuler L., Leiderman D.B., et al. Cerebral metabolism and depression in patients with complex partial seizures [published erratum appears in Arch Neurol 1992 Sep;49(9):976]. Arch Neurol 1992, 49(6):617-623.
99. Price J.L. Prefrontal cortical networks related to visceral function and mood. Ann N Y Acad Sci 1999, 877:383-396.
100. Salzberg M., Taher T., Davie M., et al. Depression in temporal lobe epilepsy surgery patients: an FDG-PET study. Epilepsia 2006, 47(12):2125-2130.
101. Gilliam F.G., Santos J., Vahle V., et al. Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction?. Epilepsia 2004, 45(s2):28-33.
102. Quiske A., Helmstaedter C., Lux S., Elger C.E. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000, 39(2):121-125.
103. Finegersh A., Avedissian C., Shamim S., et al. Bilateral hippocampal atrophy in temporal lobe epilepsy: effect of depressive symptoms and febrile seizures. Epilepsia 2011, 52(4):689-697.
104. Shamim S., Hasler G., Liew C., et al. Temporal lobe epilepsy, depression, and hippocampal volume. Epilepsia 2009, 50(5):1067-1071.
105. Richardson E.J., Griffith H.R., Martin R.C., et al. Structural and functional neuroimaging correlates of depression in temporal lobe epilepsy. Epilepsy Behav 2007, 10(2):242-249.
106. Serles W., Li L.M., Caramanos Z., et al. Relation of interictal spike frequency to 1H-MRSI-measured NAA/Cr. Epilepsia 1999, 40(12):1821-1827.
107. Guye M., Le Fur Y., Confort-Gouny S., et al. Metabolic and electrophysiological alterations in subtypes of temporal lobe epilepsy: a combined proton magnetic resonance spectroscopic imaging and depth electrodes study. Epilepsia 2002, 43(10):1197-1209.
108. Gilliam F.G., Maton B.M., Martin R.C., et al. Hippocampal 1H-MRSI correlates with severity of depression symptoms in temporal lobe epilepsy. Neurology 2007, 68(5):364-368.
109. 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med 2005, 46:1128-1135.
110. 1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 2007, 48(8):1526-1530.
111. 1A receptor binding in human temporal lobe epilepsy. Neurology 2004, 62(8):1343-1351.
112. 18F]MPPF PET study. Brain 2008, 131(Pt 10):2765-2782.
113. Davidson R.J., Jackson D.C., Kalin N.H. Emotion, plasticity, context, and regulation: perspectives from affective neuroscience. Psychol Bull 2000, 126(6):890-909.
114. Salgado P.C.B., Yasuda C.L., Cender F. Neuroimaging changes in mesial temporal lobe epilepsy are magnified in the presence of depression. Epilepsy Behav 2010, 19(3):422-427.
115. Bell B., Lin J.J., Seidenberg M., Hermann B. The neurobiology of cognitive disorders in temporal lobe epilepsy. Nat Rev Neurol 2011, 7:154-164.
116. Lin J.J., Salamon N., Lee A.D., et al. Reduced neocortical thickness and complexity mapped in mesial temporal lobe epilepsy with hippocampal sclerosis. Cereb Cortex 2007, 17(9):2007-2018.
117. Bernhardt B.C., Bernasconi N., Concha L., Bernasconi A. Cortical thickness analysis in temporal lobe epilepsy: reproducibility and relation to outcome. Neurology 2010, 74:1776-1785.
118. Beck A.T., Steer R.A., Garbin M.G. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988, 8:77-100.
119. Dabbs K., Jones J., Seidenberg M., Hermann B. Neuroanatomical correlates of cognitive phenotypes in temporal lobe epilepsy. Epilepsy Behav 2009, 15:445-451.
120. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008, 213(1-2):83-118.
121. McRae K., Hughes B., Chopra S., Gabrieli J.D., Ochsner K.N. The neural bases of distraction and reappraisal. J Cogn Neurosci 2010, 22(2):248-262.
122. 18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients. Brain 1998, 121:2067-2081.
123. 1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003, 60:749-756.
124. Mauguière F., Ryvlin P. The role of PET in presurgical assessment of partial epilepsies. Epileptic Disord 2004, 6:193-215.
125. 1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG. Neuroimage 2004, 22:886-896.
126. 18F]MPPF-PET study. Brain 2004, 127:900-913.
127. 1A receptors in the preoperative evaluation of temporal lobe epilepsy. Brain 2008, 131:2751-2764.
128. Bench C.J., Friston K.J., Brown R.G., Scott L.C., Frackowiak R.S., Dolan R.J. The anatomy of melancholia-focal abnormalities of cerebral blood flow in major depression. Psychol Med 1992, 22:607-615.
129. Drevets W.C., Videen T.O., Price J.L., Preskorn S.H., Carmichael S.T., Raichle M.E. A functional anatomical study of unipolar depression. J Neurosci 1992, 12:3628-3641.
130. Mayberg H.S. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin N Am 2003, 13:805-815.
131. Buchsbaum M.S., Wu J., Siegel B.V., et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 1997, 41:15-22.
132. Mayberg H.S., Brannan S.K., Tekell J.L., et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000, 48:830-843.
133. Fitzgerald P.B., Laird A.R., Maller J., Daskalakis Z.J. A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp 2008, 29:683-695.
134. Salzberg M., Taher T., Davie M., et al. Depression in temporal lobe epilepsy surgery patients: an FDG-PET study. Epilepsia 2006, 47:2125-2130.
135. Victoroff J.I., Benson F., Grafton S.T., Engel J., Mazziotta J.C. Depression in complex partial seizures. Electroencephalography and cerebral metabolic correlates. Arch Neurol 1994, 51:155-163.
136. 11C]methyl-l-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry 2004, 61:556-563.
137. 11C]methyl-l-tryptophan PET study. Neurochem Int 2008, 52:701-708.
138. 11C](+)McN5652. Biol Psychiatry 2002, 51:715-722.
139. Meyer J.H., Houle S., Sagrati S., et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004, 61:1271-1279.
140. Reivich M., Amsterdam J.D., Brunswick D.J., Shiue C.Y. PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression. J Affect Disord 2004, 82:321-327.
141. Parsey R.V., Hastings R.S., Oquendo M.A., et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006, 163:52-58.
142. 11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007, 62:870-877.
143. Drevets W.C., Frank E., Price J.C., et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999, 46:1375-1387.
144. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Greer P.J., Mathis C. Serotonin type-1A receptor imaging in depression. Nucl Med Biol 2000, 27:499-507.
145. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000, 57:174-180.
146. 11C]WAY-100635. Mol Psychiatry 2004, 9:386-392.
147. Parsey R.V., Oquendo M.A., Ogden R.T., et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006, 59:106-113.
148. Drevets W.C., Thase M.E., Moses-Kolko E.L., et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007, 34:865-877.
149. 11C]WAY-100635. Int J Neuropsychopharmacol 2008, 11:465-476.
150. Miller J.M., Brennan K.G., Ogden T.R., et al. Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 2009, 34:2275-2284.
151. Parsey R.V., Ogden R.T., Miller J.M., et al. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry 2010, 68:170-178.
152. 11C]WAY 100635. Int J Neuropsychopharmacol 2010, 13:785-791.
153. Lothe A, Saoud M, Bouvard S, Redoute J, Lerond J, Ryvlin P. 5-HT1A receptor binding changes in patients with major depressive disorder before and after antidepressant treatment: a pilot [18F]MPPF positron emission tomography study. Psychiatry Res in press.
154. 11C]WAY-100635. Synapse 2007, 61:523-530.
155. 1A receptors in patients with major depressive disorder. Psychol Med 2010, 40:523-528.
156. 1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007, 62:1258-1264.
157. Assem-Hilger E., Lanzenberger R., Savli M., et al. Central serotonin 1A receptor binding in temporal lobe epilepsy: a [carbonyl-(11)C]WAY-100635 PET study. Epilepsy Behav 2010, 19:467-473.
158. Innis R.B., Cunningham V.J., Delforge J., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007, 27:1533-1539.
159. Caspi A., Sugden K., Moffitt T.E., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
160. Zalsman G., Huang Y.Y., Oquendo M.A., et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry 2006, 163:1588-1593.
161. 1A receptor binding in humans. J Neurosci 2005, 25:2586-2590.
162. 1A receptor binding in healthy women. Mol Psychiatry 2005, 10:715-716.
163. 1A receptors in healthy subjects. Neuroimage 2009, 47:482-492.
164. 18F]MPPF binding potential in healthy subjects: a PET study. Behav Brain Funct 2010, 6:37.
165. McAfee A.T., Chilcott K.E., Johannes C.B., Hornbuckle K., Hauser W.A., Walker A.M. The incidence of first unprovoked seizure in pediatric patients with and without psychiatric diagnoses. Epilepsia 2007, 48:1075-1082.
166. Petrovski C.E.I., Szoecke N.C., Jones N.C., et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology 2010, 75:1015-1021.
167. Anhoury S., Brown R.J., Krishnamoorthy E.S., Trimble M.R. Psychiatric outcome after temporal lobectomy: a predictive study. Epilepsia 2000, 41:1608-1615.
168. Walter M., Henning A., Grimm S., et al. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 2009, 66(5):478-486.
169. Capizzano A.A., Jorge R.E., Acion L.C., Robinson R.G. In vivo proton magnetic resonance spectroscopy in patients with mood disorders: a technically oriented review. J Magn Reson Imaging 2007, 26(6):1378-1389.
170. Yildiz-Yesiloglu A., Ankerst D.P. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 2006, 147(1):1-25.
171. Rosenberg D.R., Mirza Y., Russell A., et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 2004, 43:1146-1153.
172. Dager S.R., Friedman S.D., Parow A., et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004, 61:450-458.
173. McCullumsmith R.E., Meador-Woodruff J.H. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 2002, 26:368-375.
174. Choudary P.V., Molnar M., Evans S.J., et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 2005, 102:15653-15658.
175. Berman R.M., Cappiello A., Anand A., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
176. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63(8):856-864.
177. Zarate C.A., Payne J.L., Quiroz J., et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004, 161:171-174.
178. Zarate C.A., Quiroz J.A., Singh J.B., et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005, 57:430-432.
179. Sanacora G., Kendell S.F., Levin Y., et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007, 61:822-825.
180. Sheline Y.I. Brain structural changes associated with depression. Depression and brain dysfunction 2006, 85-104. Taylor & Francis, London. F. Gilliam, A.M. Kanner, Y.I. Sheline (Eds.).
181. Bremner J.D., Vythilingam M., Vermetten E., et al. Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 2002, 51(4):273-279.
182. Chen M.C., Hamilton J.P., Gotlib I.H. Decreased hippocampal volume in healthy girls at risk of depression. Arch Gen Psychiatry 2010, 67(3):270-276.
183. Barioni Salgado P.C., Yasuda C.L., Cendes F. Neuroimaging changes in mesial temporal lobe epilepsy are magnified in the presence of depression. Epilepsy Behav 2010, 19:422-427.
184. Bilevicius E., Yasuda C.L., Silva M.S., Guerreiro C.A.M., Lopes-Cendes I., Cendes F. Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study. Neurology 2010, 75:1695-1701.